CAC
LSB

Cowen and Company’s LakeShore Biopharma LSB Stock Holding History

Cowen and Company’s Portfolio LSB Stock Details LSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,236
Closed -$9.88K – 688
2023
Q3 		$9.88K Buy
+1,236
New +$14.3K ﹤0.01% 460

Other funds holding LSB

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
VAM
Valliance Asset Management Central, Hong Kong $864M AUM 906.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
SCM
Superstring Capital Management New York $140M AUM 323.19% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Pinpoint Asset Management Hong Kong $576M AUM 43.65% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Cowen and Company's LSB Position: Q4 2023 in Review

Cowen and Company sold out of LakeShore Biopharma (LSB) in Q4 2023, closing a stake of 1,236 shares — an estimated $9.88K sold.

Cowen and Company first reported a position in LSB in Q3 2023 and held it in 1 quarter. The position peaked at $9.88K in Q3 2023. 10 funds tracked by Wall St. Rank hold LSB as of Q4 2023.

  • Cowen and Company reported no remaining LakeShore Biopharma position as of Q4 2023 after selling out during the quarter.
  • Cowen and Company sold 1,236 LakeShore Biopharma shares in Q4 2023, an estimated $9.88K.
  • Cowen and Company first reported a position in LakeShore Biopharma in Q3 2023 and held it in 1 quarter.
  • Cowen and Company's LakeShore Biopharma position peaked at $9.88K in Q3 2023.
  • 10 funds tracked by Wall St. Rank held LakeShore Biopharma as of Q4 2023.

Based on Cowen and Company's 13F filing for Q4 2023, filed 8 Feb 2024.